Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026
View original at finance.yahoo.comExelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026 – Cabozantinib franchise achieves approximately $2.123 billion in preliminary U.S…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
A second Merck-sponsored pivotal trial of zanzalintinib and belzutifan in RCC is anticipated to begin in early 2026
80% confidenceExelixis anticipates advancing two programs into clinical development in 2026: XL557 and XB773
80% confidenceExelixis expects to initiate STELLAR-316 in mid-2026
80% confidenceSTELLAR-316 trial represents an opportunity for zanzalintinib to become the first and only systemic therapy approved for meningioma
80% confidenceFinal analysis of STELLAR-303's second dual primary endpoint of OS in patients without liver metastases is expected mid-2026
80% confidenceSTELLAR-311 is the first study to randomize a small molecule against an active control in this setting, with potential to broadly redefine oral treatment options for NET patients
80% confidenceExelixis expects cabozantinib franchise growth to continue in 2026, building on the product's position as the leading tyrosine kinase inhibitor and oral therapy in RCC and NET
80% confidenceExelixis enters 2026 with a strong and growing commercial business, the opportunity to bring a potential second oncology franchise to market and an exciting pipeline of novel small molecules and biotherapeutics
80% confidenceThe company's momentum accelerated throughout 2025, driven by the continued strong commercial performance of CABOMETYX in renal cell carcinoma and advanced neuroendocrine tumors
80% confidenceThe company aims to establish lasting franchises in renal cell carcinoma, neuroendocrine tumors and colorectal cancer where products can be successful as monotherapies or in combination
80% confidenceExelixis believes XB773 could be a best-in-class molecule with better payload delivery compared to competitor ADCs and potential for improved therapeutic benefit
80% confidenceThrough careful prioritization and disciplined investments in high-value opportunities, the company is confident it can drive sustained near- to mid-term growth while returning capital to shareholders and improving standards of care for patients with cancer
80% confidenceExelixis is pursuing a multi-franchise approach that fosters innovation, manages risk and maximizes the value of portfolio for all stakeholders
80% confidenceExelixis expects to initiate STELLAR-201 in mid-2026
80% confidenceAs of Q3 2025, CABOMETYX was the leading oral therapy in the second-or-later line NET market, with broad uptake across 2L+ patient types and practice settings
80% confidenceTopline results for STELLAR-304 are anticipated mid-2026
80% confidenceExelixis believes XL557 has the potential to become a best-in-class molecule that could serve NET patients across all lines of treatment as a monotherapy and potentially in combination with zanzalintinib
80% confidenceAs of Q3 2025, CABOMETYX was the market leader as the number one TKI monotherapy and most prescribed TKI in combination with immunotherapy in RCC
80% confidenceExelixis anticipates 2026 will be a significant year of clinical, regulatory and commercial progress as the company grows its current cabozantinib business, works toward building a potential second commercial franchise with zanzalintinib and moves its earlier stage pipeline forward
80% confidenceExelixis' goal is to become a top-5 solid tumor oncology company
80% confidence